Analyst: Lilly doesn't overshadow semaglutide in spite of strong data

Even though Eli Lilly presented strong data in a comparison study between this company's drug tirzepatide and Novo Nordisk's rival semaglutide, it'll take more to eliminate the Danish competition, according to an analyst.
Photo: Sydbank/PR
Photo: Sydbank/PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

On Thursday, US pharmaceutical firm Eli Lilly has presented convincing data in favor of the drug candidate tirzepatide, which is a GLP-1 analog.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading